A Carmellose sodium, low-substituted CEP of the European Pharmacopoeia monograph is often referred to as a Carmellose sodium, low-substituted Certificate of Suitability (COS). The purpose of a Carmellose sodium, low-substituted CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Carmellose sodium, low-substituted EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Carmellose sodium, low-substituted to their clients by showing that a Carmellose sodium, low-substituted CEP has been issued for it. The manufacturer submits a Carmellose sodium, low-substituted CEP (COS) as part of the market authorization procedure, and it takes on the role of a Carmellose sodium, low-substituted CEP holder for the record. Additionally, the data presented in the Carmellose sodium, low-substituted CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Carmellose sodium, low-substituted DMF.
A Carmellose sodium, low-substituted CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Carmellose sodium, low-substituted CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Carmellose sodium, low-substituted suppliers with CEP (COS) on PharmaCompass.